burger

A pharmaceutical company
specialising in biological
medicinal products

3 fields of therapy
  • Immunology
  • Haemostasis
  • Intensive Care
4

Bioproduction sites in France

7 th largest player
worldwide

plasma derivatives

21 plasma derived
medicines

prescribed to

hospital

€ 490 M in turnover

in 2017

22

medical specialties that regularly use
LFB’s medicines

12% of turnover

invested in R&D in 2017

Meeting with

Denis DELVAL ,
Chairman and CEO of the LFB Group

" my ambition is to build the future of the Group with the men and women of the LFB. "

CELLforCURE will produce innovative cancer CAR-T treatments for Novartis

All news

2:19

LFB Group corporate film

Usine 2020 : produire en France pour le monde entier

02:17

LFB next-generation facility in Arras: manufacturing in France for the whole world

All videos

CELLforCURE will produce innovative cancer CAR-T treatments for Novartis
Denis Delval pdg

Denis DELVAL is appointed CEO of LFB SA

2017 Rare Disease Day : LFB’s commitment in the field of rare diseases

LFB’s fibrinogen and 10% immunoglobulin authorized for use in Europe

Inauguration of new industrial facilities at the LFB biotech plant in Alès (Gard)

Belgium: acquisition of CAF-DCF by LFB
21 plasma derived
medicines

prescribed to

hospital
12% of turnover

invested in R&D in 2017
4

Bioproduction sites in France
7th largest player
worldwide

plasma derivatives
Usine 2020 : produire en France pour le monde entier

02:17

LFB next-generation facility in Arras: manufacturing in France for the whole world

there is 3 years

2:19

LFB Group corporate film

there is 3 years